Search Results 351-360 of 14460 for albumin

1. Respiratory Physiology of Escalating Doses of Nalbuphine Extended-Release Tablets in Patients with IPF - Mayo Clinic

   Liver Function: Total Bilirubin >3mg/dL [>50umol/L] and Serum Albumin <2.8g/dl at screening. Subjects with a history of over sedation or a current clinical ...

2. Cervical Cancer Clinical Trials - Mayo Clinic Research

   Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either ...

3. Publications - Beau Toskich, M.D. - Mayo Clinic

   Mapping angiography and transarterial technetium macroaggregated albumin particle simulation of recurrent atypical intracranial meningioma: feasibility for ...

4. RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC - Mayo Clinic

   - Serum albumin ≥2.8 g/dL - Aspartate aminotransferase and alanine aminotransferase (ALT) ≤ 3.0 × ULN (or ≤ 5.0 × ULN, if liver metastases are present) ...

5. Study to Evaluate Chemoembolization Combined with Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma - Mayo Clinic

   Albumin ≥2.8 g/dL;; International normalized ratio ≤1.6;; 2+ proteinuria or less urine dipstick reading;; Calculated creatinine clearance (CL) ≥ 30 mL/min ...

6. Efficacy and Safety of Treatment With Alpelisib Plus Endocrine Therapy in Patients With HR+, HER2-negative aBC, With PIK3CA Mutations, Whose Disease Has Progressed on or After CDK 4/6 Treatment With an Aromatase Inhibitor (AI) or Fulvestrant - Mayo Clinic

   Patient has potassium, magnesium and calcium (corrected for albumin), within normal limits (either by central or local lab), or ≤ Grade 1 severity according to ...

7. A Study to Evaluate Preoperative Oral Microbiota-Based Investigational New Drug to Target Immune Response in Patients with Operable Stage I-III Breast Cancer - Mayo Clinic

   Albumin ≥ 3 g/dL. Willing and able to swallow capsules. Willing and able to complete the stool and serum testing required for the study. Willing to provide ...

8. MELD calculator - Medical Professionals - Mayo Clinic

   Mayo Clinic MELD Model calculator used to determine the survival probability of a patient with end stage liver disease, for use by medical professionals.

9. Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer - Mayo Clinic

   Serum Albumin ≥ 2.8 g/dL. For women of childbearing potential only: a negative urine or serum pregnancy test done ≤ 7 days prior to pre-registration is ...

10. Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia - Mayo Clinic

    Albumin ≥ 2.5 mg/dL. Willing and able to comply with all aspects of the protocol. Provide written informed consent prior to any study-specific Screening ...